Long-term efficacy of adalimumab in elderly patients with rheumatoid arthritis and associated risk factors

ADA combined with MTX significantly improves disease activity and functional outcomes in elderly patients with RA, demonstrating sustained long-term efficacy and acceptable safety. For patients with a high baseline inflammatory burden, combination therapy should be prioritized, with individualized management guided by risk stratification.